Pharmaxis Begins U.S. Operations

Australia’s Pharmaxis has established a Philadelphia, Pa.-based subsidiary to serve the North American market.

The subsidiary will help pave the way for the commercialization of both Aridol, a test for airway inflammation, and Bronchitol, a treatment for lung diseases, in the U.S.

Alan Robertson, Pharmaxis’ CEO, said the company plans to start two U.S. Phase III trials of Bronchitol in the first quarter of 2008 and file a new drug application for Aridol with the FDA.